Keywords: Kidney, Kidney, Hyperpolarized 13C MRI, renal cell carcinoma, pyruvate, treatment response
Motivation: Hyperpolarized (HP) 13C-pyruvate metabolic MRI may provide a solution to the pressing unmet need to discriminate early therapeutic response vs resistance in advanced renal cell carcinoma (RCC).
Goal(s): To evaluate, for the first time, whether pyruvate-to-lactate conversion (kPL) is an early and sensitive response marker to systemic RCC therapies.
Approach: Three patients with advanced RCC underwent HP MRI at baseline and again 3–4-week after treatment initiation (N=2).
Results: HP 13C MRI detected a 50–100% kPL decrease at 4-weeks, prior to definitive clinical radiographic response (~3 months). Inter- and intratumoral metabolic heterogeneity may inform on subsequent therapeutic efficacy.
Impact: Management of advanced/metastatic RCC in the salvage setting is challenging and options are limited. Our initial positive findings highlight how HP 13C MRI’s unique sensitivity to early treatment response/resistance may be leveraged to improve outcomes and avoid toxic, ineffective therapies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords